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INTRODUCTION: The incidence of brain metastasis due to breast cancer is increasing, and prognosis is poor.
Treatment is challenging because the blood-brain barrier (BBB) limits efficacy of systemic therapies. In this work,
we develop a clinically relevant whole brain radiotherapy (WBRT) plan to investigate the impact of radiation on
brain metastasis development and BBB permeability in a murine model. We hypothesize that radiotherapy will
decrease tumor burden and increase tumor permeability, which could offer a mechanism to increase drug uptake
in brain metastases. METHODS: Contrast-enhanced magnetic resonance imaging (MRI) and high-resolution
anatomical MRI were used to evaluate BBB integrity associated with brain metastases due to breast cancer in the
MDA-MB-231-BR-HER2 model during their natural development. Novel image-guided microirradiation technology
was employed to develop WBRT treatment plans and to investigate if this altered brain metastatic growth or
permeability. Histology and immunohistochemistry were performed on whole brain slices corresponding with MRI
to validate and further investigate radiological findings. RESULTS: Herein, we show successful implementation of
microirradiation technology that can deliver WBRT to small animals. We further report that WBRT following
diagnosis of brain metastasis can mitigate, but not eliminate, tumor growth in the MDA-MB-231-BR-HER2 model.
Moreover, radiotherapy did not impact BBB permeability associated with metastases. CONCLUSIONS: Clinically
relevant WBRT is not curative when delivered after MRI-detectable tumors have developed in this model. A dose
of 20 Gy in 2 fractions was not sufficient to increase tumor permeability such that it could be used as a method to
increase systemic drug uptake in brain metastasis.
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The relative 5-year survival for breast cancer patients has steadily
increased and was recently reported at 90% in the United States [1].
Now, the major challenge of this disease is its ability to metastasize to
distant sites where detection and therapy become complicated. The
incidence of metastasis to the brain is especially high for women with
breast cancer that overexpresses the human epidermal growth factor
receptor 2 (HER2) and has been reported at 25% to 48% [2–4].
More concerning is that brain metastases often manifest while
metastases outside of the brain are still responding to successful
anti-HER2 therapies, such as trastuzumab (Herceptin). Several
factors may be involved in this type of mixed response, including
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genetic alterations distinct from the primary tumor [5,6]. Notably,
the inability of traditional systemic therapies to penetrate the intact
blood-brain barrier (BBB) to any significant degree, or at all, presents
a significant obstacle for drug delivery, thus rendering the brain a
sanctuary site for metastatic growth [7,8].
In the absence of effective systemic therapy, treatment options for
patients with brain metastases are limited; they include steroids,
surgical excision of solitary metastases, stereotactic radiosurgery for
small lesions not amenable to surgery, and whole brain radiotherapy
(WBRT). Although combinations of these options have improved
prognosis, the median survival time of patients with HER2+ breast
cancer is only 11.5 to 16.5 months after diagnosis of brain metastasis
[9]. The clinical standard for treating multiple [e.g. more than three
lesions detected by magnetic resonance imaging (MRI)] brain
metastases and diffuse disease is WBRT; however, this treatment is
palliative. Response to treatment may be improved by optimizing the
timing of radiotherapy in combination with systemic therapies. Some
studies suggest that radiation can increase vascular permeability
within tumors and in healthy brain tissue [10,11]. If WBRT increases
permeability of the local BBB in vivo, it may be possible to increase
drug uptake in brain metastases and improve on the results of
systemic therapy or radiotherapy alone [12].
Several contrast agents with varying sizes have been used to assess
BBB integrity and degree of permeability. Under normal conditions,
the intact BBB prevents extravasation of contrast agents. Damage to
the BBB can therefore be evaluated based on the size, charge, and
composition of contrast agents that are able to cross the BBB
and accumulate in the brain. Traditionally, BBB permeability has
been studied by microscopy using agents such as sodium fluor-
escin (376 Da), Texas red dextran (3 or 70 kDa), horseradish
peroxidase (44 kDa), or albumin-bound Evans blue dye (69 kDa)
[8,10,13–15]. These techniques are limited by their ex vivo nature,
inability to monitor changes over time, and contrast agent sizes
that are not directly relevant to drug uptake. In this work, we
evaluate BBB integrity in vivo over time using gadolinium-enhanced
(Gd) MRI, which is routinely used in clinical diagnosis to identify
BBB breakdown.
Gd-enhanced MRI has also been used in preclinical cancer models
to evaluate BBB permeability associated with brain tumors
[14,16–19]. Regions where the BBB has been compromised can be
visualized because of local accumulation of the Gd contrast agent,
which results in signal enhancement (brightness) in the image. Using
this method, substantial heterogeneity has been reported in the
permeability of brain metastases. In addition, both Gd-permeable as
well as Gd-impermeable tumors have been observed within the same
brain [17,19]. Notably, Percy and colleagues also found that many
metastases were impermeable to Gd early in development but became
permeable over time [17]. Here, we build on these results by
investigating whether radiation therapy increases the permeability of
brain metastases to understand if it is possible to open a window
where systemic therapy could have increased efficacy.
In this study, we developed a clinically relevant WBRT treatment
protocol that is feasible in the MDA-MB-231-BR-HER2 experi-
mental brain metastatic breast cancer model. We used this model
along with contrast-enhanced MRI and high-resolution anatomical
MRI to investigate the impact of clinically relevant radiation
treatment on the growth of brain metastases due to breast cancer
and on BBB integrity in a murine model. We hypothesized thatradiotherapy will decrease the tumor burden in treated animals and
increase tumor permeability.
Methods
Cell Culture
The brain metastatic breast cancer cells (MDA-MB-231-BR-
HER2) used in this research were a kind gift from Dr. Patricia Steeg’s
laboratory at the National Cancer Institute (Bethesda, MA) [20,21].
Cells were grown in Dulbecco’s modified Eagle’s medium with 10%
fetal bovine serum and 1% penicillin and streptomycin, and were
maintained at 37°C and 5% CO2. The cell line was tested for
mycoplasma contamination using the MycoAlert Mycoplasma
Detection Kit (Lonza, Rockland, ME) and was found to be negative.
The trypan blue exclusion assay was used to determine cell viability.
Animal Preparation
Female nude mice (nu/nu, aged 6-8 weeks from Charles River
Laboratories, Wilmington, MA) were housed in a pathogen-free
barrier facility at Robarts Research Institute. All experiments were
approved by the Animal Use Subcommittee of the University Council
on Animal Care at the University of Western Ontario. Mice (n = 2 for
commissioning, n = 12 for WBRT experiment) were anesthetized
with 2% isoflurane in oxygen and given an intracardiac injection of
100,000 MDA-MB-231-BR-HER2 cells suspended in 0.1 ml of
Hank’s balanced salt solution. Mice were euthanized by an overdose
injection of pentobarbital (Euthanyl) after the final imaging session.
Radiotherapy
We previously developed an integrated micro-computed tomog-
raphy (CT)/RT system capable of sophisticated image-guided
conformal small-animal radiotherapy [22]. The microirradiation
technology is based on a modified preclinical micro-CT system (GE
eXplore CT 120, GE Healthcare, Milwaukee, WI) with an upgraded
x-ray generator (140 kVp, 50 kW), custom irradiation control
software (Parallax-Innovations, London, ON, Canada), and a
custom-built computer-controlled collimator. Thus far, it had been
used for respiratory-gated rat lung irradiation and was commissioned
for mouse WBRT in this work [22,23]. Mice were anesthetized
(1.5% isoflurane in oxygen), placed feet first prone on the rodent
couch, and aligned using setup lasers and CT imaging. On-board
fluoroscopy was used to identify the skull and position computerized
collimators such that the whole brain was targeted for irradiation and
the remainder of the head and body was shielded. Animal
temperature was maintained using a heating pad, and breathing
rate was monitored during treatment.
Magnetic Resonance Imaging
Magnetic resonance images were acquired on a 3.0-T GE Excite
MR750 clinical scanner (General Electric, Mississauga, ON, Canada)
using a custom-built gradient insert coil (inner diameter = 17.5 cm,
gradient strength = 500 mT/m, and peak slew rate = 3000 T/m per
second). Mice were anesthetized (1.5% isoflurane in oxygen) and
placed in a custom solenoidal mouse head radiofrequency coil (inner
diameter = 1.5 cm). Animal temperature was maintained using warm
saline bags during imaging. Anatomical balanced steady-state free
precession (bSSFP) scans were acquired with the following
parameters: spatial resolution = 100 × 100 × 200 μm, repetition
time = 8 milliseconds, echo time = 4 milliseconds, flip angle = 35°,
signal averages = 2, radiofrequency phase cycles = 8, and scan time =
Figure 1.Micro-CT/RT targeting for mouse WBRT. Fluoroscopy-guided collimation of the mouse brain (A, B) allows for precise delivery of
the 10-Gy per fraction treatment plan. Dosimetry was verified using a Monte Carlo dose calculation, where the 10-Gy isodose line is
delineated in green (C). The brain received a uniform dose of 10 Gy. Enhanced dose to the skull is observed due to the low energy of the
beam (140 kV) where photoelectric effect is prominent.
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T1-weighted spin echo (T1w SE) images were acquired at approximately
45 minutes after an intraperitoneal injection of 0.2 ml gadopentetate
dimeglumine (Magnevist, 0.5 mmol/ml). The parameters were spatial
resolution = 156 × 156 × 400 μm, repetition time = 600 milliseconds,
echo time = 20 milliseconds, signal averages = 8, and scan time =
20 minutes. ZIP512 upscaling was applied.
Data Analysis
Open-source OsiriX image software (version 3.9.2) was used for
image analysis. Brain metastases were counted, and the boundaries of
each were manually segmented using the ROI tool in every bSSFP
slice throughout the whole mouse brain. Tumor volume was then
calculated by a three-dimensional reconstruction using the Osirix
volume algorithm. Enhancing fraction (reflecting Gd-permeable
tumors) was determined as previously described by comparing tumor
detection in corresponding post-Gd T1w SE and bSSFP im-
ages [17,19]. Metastases that are detected in both the post-Gd T1w
SE and the bSSFP sequences are considered “enhancing”; tumors
appearing in only the bSSFP images are “nonenhancing.” Tumorsdetected in bSSFP without a corresponding T1w SE image slice were
excluded from the enhancement analysis.
Statistical analysis was performed using GraphPad Prism version 6.0
software (GraphPad, San Diego, CA). Where two groups were
compared, two-way paired or unpaired Student’s t tests were performed.
Where two groups were compared over multiple time points, two-way
repeated-measures analyses of variance were performed. For
enhancement-related statistical analyses over time, one untreated
mouse was removed because of unsuccessful injection on day 32;
therefore, repeated measures were not used for this analysis. Post hoc
analysis included Sidak’s multiple-comparisons tests.
Histology and Immunohistochemistry
At experimental end point, mice were first perfused with 0.9% saline
before perfusion fixation with 4% formalin. Brains were then excised and
further fixed for 24 hours by immersion in 4% formalin. Fixed brains were
then processed, paraffin embedded, and cut into 5 μm sections. Brain
sections were then stained with hematoxylin and eosin (H&E) for
morphology, or immunohistochemistry was performed for either the
proliferation marker Ki67, or for human mitochondria markers (clone
Figure 2. Response to radiation-induced DNA DSB was visualized by fluorescent γ-H2AX immunohistochemistry. This staining was
performed 30 minutes postradiotherapy with fluorescent γ-H2AX (red foci) on a nuclear DAPI background (blue) on whole brain sections
of untreated (A) and WBRT-treated (B) mouse brain. Magnified images of untreated tumor (C) and normal brain (D) showed minimal
γ-H2AX signal intensity compared with irradiated tumor (E) and irradiated normal brain (F). Confocal microscopy illustrated that the
accumulation of γ-H2AX was within the nuclei of tumor cells; untreated nuclei had few intrinsic γ-H2AX foci (G), and treated nuclei had
many γ-H2AX foci in response to radiation-induced DNA DSB. Scale bars are 750 μm (A,B), 50 μm (C–F), and 20 μm (G,H).
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using heat-mediated antigen retrieval with citrate buffer pH 6. Tissue
sections were blocked with Dako Protein Block, Serum-Free (Dako
Canada, Inc., Burlington, ON, Canada), and incubated with anti-ki67
(1:100, ab833, Abcam Inc.) rabbit polyclonal antibodies. Positive staining
was detected using Dako LSAB2 system-HRP (Dako Canada Inc.) and
Vector DAB peroxidase substrate kit (Vector Laboratories, Burlingame,
CA) according to manufacturer’s instructions. Mouse anti-human
mitochondria antibody (clone MTCO2, 1:100) was used with the Dako
Animal Research Kit according tomanufacturer’s instructions for detection
of human cells. All sections were counterstained with hematoxylin.
For commissioning studies, mice were perfused with 0.9% saline
before perfusion fixation with 4% paraformaldehyde; brains were
excised, further fixed for 24 hours by immersion in 4% formalin,
placed in ascending sucrose gradients (10%, 20%, 30%), embedded
in optimal cutting temperature compound (Tissue-Tek, Sakura,
Torrance, CA), frozen, cryosectioned with 10-μm thickness, and
stained by immunohistochemistry for γ-H2AX using the Ford
protocol [24]. Sections were incubated with mouse anti–γ-H2AX
antibody (1:700, anti–phospho-histone H2AX, Ser139, clone
JBW301; Millipore, Billerica, MA) overnight and then stained with
secondary antibody Alexa-Fluoro 594 goat anti-mouse IgG (1:500,
Life Technologies, Carlsbad, CA) for 1 hour at room temperature. All
sections were counterstained with 4',6-diamidino-2-phenylindole
(DAPI) and mounted with antifade medium Vectashield (Vector
Laboratories, Inc., Burlington, ON, Canada).
All staining was imaged on an Axio Imager A1 microscope (Zeiss
CANADA, Toronto, ON, Canada) with a Retiga EXi (QImaging
Scientific Research Cameras, Surrey, BC, Canada) digital camera.
Whole brain histology images were acquired using the TISSUEscope4000 (Huron Digital Pathology, Waterloo, ON, Canada). For
γ-H2AX confocal images, an inverted confocal microscope (Olympus
Fluoview FV1000 Confocal Imaging System) was used.
Results
Radiation Therapy Planning and Verification
First, the integrated micro-CT/RT system used in this research was
implemented for mouse WBRT. A treatment plan of 20 Gy in two
fractions on consecutive days was decided based on the biological
effective dose to tumor (assuming α/β=10) to be equivalent to the
clinical WBRT dose fractionation scheme of 30 Gy/10. Image
guidance allowed for precise isolation of the mouse brain in a
collimated 10 × 14–mm field; fluoroscopy images show the
uncollimated field (Figure 1A) and collimated field (Figure 1B).
The brain was irradiated with two identical fields using a
parallel-opposed beam setup. One beam was delivered from the
animal’s left-right direction and one from right-left, for a cumulative
dose of 10 Gy per fraction. A Monte Carlo dose verification
calculation was performed to confirm delivery of the treatment plan
(10 Gy is shown by a green line) (Figure 1C). Mean dose rate was
0.12 ± 0.01 Gy/min.
Immunohistochemistry was performed after irradiation to confirm
adequate whole brain coverage by the radiotherapy plan.
Irradiation-induced DNA damage response was verified by fluores-
cent γ-H2AX immunohistochemistry and the DAPI nuclear stain;
this confirmed the actual whole brain radiation field in tissue. Whole
brain sections bearing MDA-MB-231-BR-HER2 metastases were
imaged with a fluorescent microscope at 10× magnification; these
showed no damage to unirradiated mouse brain (Figure 2A) and
Figure 3. Representative MRI with correlative histology and immunohistochemistry of metastases in the MDA-MB-231-BR-HER2 brain
metastasis model. Staining for H&E (left column), Ki67 (middle column), and humanmitochondria (right column) at 10×magnification (top
row, white scale bar = 250 μm) and 40×magnification (bottom row, black scale bar = 100 μm) supports the imaging data and confirmed
that MRI-detected lesions were proliferative cancerous tumors of human origin.
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DNA double-stranded breaks (DSB, red foci) across the whole treated
mouse brain 30 minutes after the second fraction of 20 Gy/2
(Figure 2B). Intrinsic DNA DSB response was evaluated in 100×
magnification images of tumor tissue and normal brain of an
unirradiated mouse (Figure 2, C and D) and compared with initial
DNA DSB response in a mouse brain 30 minutes postirradiation
(Figure 2, E and F). Increased γ-H2AX intensity is evident in
both tumor and normal brain tissue in the mouse brain treated
with whole brain radiotherapy compared with untreated. Confocal
microscopy confirms accumulation of γ-H2AX within the nuclei
of tumor cells. Whereas few intrinsic γ-H2AX foci are present in
nuclei of unirradiated tumor cells (Figure 2G), they are highly
prevalent in response to DNA DSB at 30 minutes postirradiation
(Figure 2H).Brain sections were also assessed at end point (day 36 post–cell
injection) to confirm imaging results, evaluate proliferation in
tumors, and verify human status of the developing cancer (Figure 3).
Hyperintense regions in the MRI corresponded to tumor regions as
assessed by morphology in standard H&E histology. Ki67 staining of
neighboring sections indicated that the detected tumors were
proliferative. Staining for human mitochondria also confirmed that
the metastases were of human origin. The histology and immuno-
histochemistry therefore validate that the MRI findings in this study
reflect cancerous growth due to the injected MDA-MB-231-BR-
HER2 cell line.
WBRT Experiment
Next, the micro-CT/RT system was used to deliver WBRT (20
Gy/2) to nude mice with brain metastatic breast cancer. Treatment
Figure 4. Representative images of metastases due to MDA-MB-
231-BR-HER2 human brain metastatic breast cancer on day 36.
bSSFP MRI illustrated metastasis burden by the appearance of
hyperintensities (A), and this corresponded with tumor detection in
H&E-stained sections (B).
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tumors (day 24 and 25 post–cell injection); this timing mimics the
usual treatment following diagnosis that occurs in the clinic. Three
dimensional, high-resolution anatomical bSSFP MRI was used to
detect and monitor tumor progression over time. Radiological
findings correspond well with tumor burden in whole brain histology
sections (Figure 4).
The number of tumors, total tumor volume, and mean tumor
volume over time (day 23, 32, and 36) were quantified in bSSFP
images, and these data are presented in Table 1. WBRT did not
have an effect on the number of tumors or on total tumor volume
over time; however, it did have an effect on the mean volume of a
tumor over time (P b .01); post hoc analysis found that mean tumor
volume was significantly less in WBRT-treated mice than untreated
(P b .001).Table 1. Quantification Tumor Incidence, Burden, and Mean Tumor Volume from MRI in the Tra
Analysis Day 23 Day 32
Untreated WBRT Untreated WBRT
Number of tumors 7.0 ± 11 25 ± 29 17 ± 19 34 ± 3
Total tumor volume (mm3) 0.26 ± 0.41 0.98 ± 1.4 4.9 ± 5.8 8.3 ± 9
Mean tumor volume (mm3) 0.030 ± 0.022 0.035 ± 0.014 0.33 ± 0.18 0.23 ± 0
The number of tumors and total tumor volume in the mouse brain increased over time from day 23
WBRT had a significant effect on mean tumor volume over time; post hoc analysis between groups indi
Data are presented as mean ± SD. N = 6 for each group.Substantial variability was observed in tumor response after
WBRT. The changes in volume of 209 treated tumors were analyzed
between 7 and 11 days posttreatment (day 32 and 36). A paired
two-tailed t test found no significant difference between the fraction
of tumors that decreased in volume after WBRT compared with the
fraction that increased (Figure 5A). Furthermore, despite the same
treatment plan, some mice had more tumors that decreased in volume
after radiotherapy than others. For example, as shown in Figure 5B,
85% of the brain tumors in mouse B had a decreased volume after
WBRT, whereas only 15% of the tumors in mouse E had a decreased
volume after WBRT.
Next, BBB integrity was evaluated by determining the ability of Gd
to accumulate within tumors and cause increased signal intensity
(enhancement). Analysis of BBB permeability by enhancement in
T1w SE post-Gd images was performed as previously described, and
representative MR image slices of the same mouse brain are shown in
Figure 6, A and B [17,19]. The enhancing fraction over time is
shown in Figure 6C. Over time, a higher proportion of enhancing
metastases are detectable in both groups (P b .0001). Of the
nonenhancing tumors present in untreated mice (black bars) on day
32, 29% (9 of 31) changed to enhancing by day 36. Similarly, 26% (6
of 23) of nonenhancing tumors in WBRT mice (white bars) changed
to enhancing in the same time frame. WBRT did not increase the
fraction of enhancing tumors.
Temporal analysis of enhancement status and mean tumor volume
(Figure 7) found that enhancing tumors grow larger than none-
nhancing tumors over time in both untreated and WBRT-treated
groups (P b .001 and P b .01, respectively). Post hoc analysis found
that enhancing tumors are significantly larger than nonenhancing on
day 32 and 36 in both groups (untreated: ••P b .05, •P b .0001.
WBRT: °°P b .0001, °P b .0001). Radiotherapy affected the growth
of enhancing and nonenhancing tumors differently (Figure 7, striped
versus solid bars). Over time, WBRT had an increased effect on the
size of enhancing tumors (P b .01); post hoc analysis between
treatment groups showed that the mean volume of enhancing tumors
is significantly less in WBRT-treated mice compared with untreated
on day 36 (*P b .0001). Contrarily, time and treatment group did not
affect the volume of nonenhancing tumors.
Discussion
This research used high-resolution anatomical and contrast-enhanced
MRI in a murine model of breast cancer brain metastasis to
monitor tumor development and permeability in vivo. This was
combined with novel image-guided microirradiation technology to
provide insight into the responses of tumors and alternations in BBB
integrity in a clinically relevant model of breast cancer brain
metastasis and WBRT.ditional WBRT Experiment
Day 36 Main Effect
Untreated WBRT
3 18 ± 19 34 ± 33 Time P b .0001
.8 9.8 ± 11 8.4 ± 9.3 Time P b .01
.067 0.67 ± 0.40* 0.23 ± 0.059* Interaction between time and treatment P b .01
to 36, but there was no difference between treatment groups for these measurements. Traditional
cated that, by day 36, on average, tumors were smaller in treated mice compared with untreated (*).
Figure 5. Treatment response was heterogeneous after traditional WBRT. There was no significant difference between the fraction of
tumors that decreased in volume after traditional WBRT and the fraction that continued to increase (A). In addition, the response to
therapy wasmarkedly different for eachmouse, ranging from 15% to 85% of the tumors in a mouse brain being reduced in tumor volume
following treatment (B). Error bars are standard deviation.
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successfully applied to deliver mouse whole brain irradiation. These
are the first experiments where such a system has been used to
demonstrate the effects of WBRT on brain metastatic development.
This technology has the capacity to target and deliver conformal
irradiation to the mouse brain via onboard image-guided collimation.
Postirradiation, γ-H2AX staining confirmed that response to
radiation-induced DNA DSB was present and was uniform across
the whole mouse brain. Dose rate was low compared with otherFigure 6. Tumor permeability visualized and quantified over tim
Gd-permeable tumors) was quantified as the number of enhancing
post-Gd (A) and bSSFP images (B). Black arrows indicate metastases
these were considered “enhancing.” White arrows indicate metastas
corresponding post-Gd T1w SE image; these were considered “non
groups; treatment did not have any significant effect (C). Error bars rpreclinical irradiators; however, doses up to 20 Gy per fraction can be
delivered in one session, and increased dose can compensate for the
lower dose rate [25,26]. Here, we chose 20 Gy/2 to keep side effects at
a minimum while delivering biological effective doses that are relevant
for WBRT.
Using this small-animal irradiation system, traditional WBRT was
given after MRI detected tumors; this sequence, where treatment
follows diagnosis, is the usual order of events in the clinic. WBRT was
able to mitigate tumor growth, although it could not eliminate thee by contrast-enhanced MRI. Enhancing fraction (representing
tumors relative to total tumor burden by assessment of T1w SE
that were detected in both the T1w SE and the bSSFP sequences;
es that were detected in the bSSFP image but were absent in the
enhancing.” Over time, the enhancing fraction increased in both
epresent standard deviation.
Figure 7. Enhancing and nonenhancing tumors respond differently to WBRT. In both untreated and WBRT-treated mice, enhancing
tumors were larger than nonenhancing tumors at day 32 and at day 36 (statistical significance indicated by ••, •, °°, and °). By day 36, the
mean volume of an enhancing tumor in a treated mouse was significantly less than untreated (*); however, there was no difference
between groups in the volume of nonenhancing tumors. Error bars represent standard deviation.
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who observed that fractionated (3 Gy × 10 fractions, starting on day
14 postinjection) or single-dose (15 Gy × 1 fraction on day 14)
radiotherapy could reduce, but not eliminate, the number of large and
micrometastases in the 231-BR experimental brain metastasis model
[27]. In our study, the largest contributor to the drop in mean tumor
volume of treated animals was a decrease in the mean volume of
enhancing tumors. On the contrary, nonenhancing tumor volumes,
although significantly less by comparison, were not different between
treatment groups. Increased BBB permeability with tumor size, in
addition to innate BBB heterogeneity, has been reported by several
groups and investigated for its impact on systemic drug delivery
[8,17,18,28,29]. However, to the best of our knowledge, this is the
first report indicating that impermeable tumors may not respond to
radiotherapy in the same way as their permeable counterparts.
Increased vascular permeability and BBB disruption after irradi-
ation have been well documented [10,11,30]. This stimulated the
idea that radiotherapy may be a useful mechanism to improve
chemotherapeutic efficacy by increasing drug uptake though
breakdown of the BBB, which is usually prohibitively exclusive to
anticancer drugs. Yet, clinical studies investigating combinations of
chemo- and radiotherapy remain inconclusive [31–33]. Previous
studies may have offered poor insight due to limitations by their
in vitro or ex vivo nature, nontranslational animal models, and
irradiation doses that are not clinically relevant [10,11]. Moreover,
no study has looked at these effects in the context of brain metastasis.
Our study addresses all of these limitations; we used MRI tumor
enhancement post-Gd administration to assess tumor permeability
in vivo and found that the fraction of enhancing tumors was not
different between treated and untreated mice at any time point.
Furthermore, the percent of tumors that change from nonenhancing
to enhancing was similar after WBRT compared with untreated.
Notably, tumor enhancement post-Gd administration reflects
sufficient BBB permeability to allow the 590-Da Gd-based contrast
agent to cross; this is approximately the same molecular weight as
lapatinib (581Da), a dual tyrosine kinase inhibitor used in combination
therapy for HER2+ metastatic breast cancer patients. Taskar and
colleagues previously reported that limited BBB permeability in the vast
majority of brain metastases contributed to poor therapeutic efficacy for
this drug [28]. Our study, using Gd as a permeability marker, did notfind a suitable mechanism to increase tumor permeability. Our results
suggest that increased BBB permeability due to clinically relevant
radiotherapy, as measured by enhancement post-Gd administration, is
not present at 1 week or 11 days post-WBRT as was previously
hypothesized [12]. Moreover, the idea that radiotherapy can increase
BBB permeability and thereby improve drug delivery is not feasible in
this model.
In summary, this research developed technology for image-guided
mouse WBRT and used it with high-resolution anatomical and
contrast-enhanced MRI to investigate tumor and BBB response after
radiotherapy in a mouse model of breast cancer brain metastasis.
Contrary to previous hypotheses, increased tumor permeability after
radiotherapy was not found, although enhancing tumors decreased in
volume after radiotherapy and nonenhancing tumors did not.
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